Merck & Co. , Inc. operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Merck & Co. with three other
companies in this sector in the United States:
Sanofi S.A.
(2018
sales of $42.04 billion
of which 69%
was Pharmaceuticals),
GlaxoSmithKline plc
($41.01 billion
of which 56%
was Pharmaceuticals), and
Bayer AG
($46.64 billion
of which 42%
was Pharmaceuticals & Biological Products).
Sales Analysis.
Merck & Co. reported sales of $42.29 billion
for the
year ending
December of 2018.
This
represents
an
increase of 5.4%
versus 2017, when the company's sales were $40.12 billion.
This was the third consecutive year of growth at Merck & Co. .
The sales level in 2018 was fairly close to the level five years ago: in 2013, Merck & Co. had sales
of $44.03 billion.
Sales of Merck Pharmaceutical saw an increase
of
6.5% in 2018, from
$35.39 billion to $37.69 billion.
Not all segments of Merck & Co. experienced an increase in sales in 2018:
sales of All Other fell 94.1% to $250.00 million.
Merck & Co. also experienced decreases in sales in
Unallocated (down 68.9% to $143.00 million)
.